Proactive Investors - Run By Investors For Investors

Microbot Medical shares pop on clinching of new European patent

The micro-robotic medical technology company has won a European patent for its ViRob technology platform, which is an autonomous crawling micro-robot that can navigate and crawl in different spaces within the body
depiction of body on screen
The miniature dimensions of Microbot's ViRob technology allow it to navigate and crawl in different spaces within the body

Shares of Microbot Medical Inc (NASDAQ:MBOT) almost doubled in Monday’s pre-market session after the micro-robotic medical technology company clinched a European patent for its ViRob technology platform.

The European Patent Office has granted a patent which covers Microbot’s autonomous crawling micro-robot which can be controlled remotely or within the body.

READ: Microbot Medical shares rise 10% on patent news

The new approval by European regulators means the Hingham, Massachusetts-based company now has 30 issued patents and 18 patent applications pending.

“The allowance of this European patent application further strengthens our global intellectual property estate covering our micro-robotic technology platform,” said CEO Harel Gadot.

Investors applauded the news, sending Microbot shares up 69.6% to $4.07 before the opening bell on Monday.

Microbot, which was set up in 2010 and kicked off operations in 2011, went public on Nasdaq in November 2016. The company specializes in micro-robotic medical technologies, leveraging the natural and artificial lumens within the body. 

The miniature dimensions of Microbot’s ViRob technology allow it to navigate and crawl in different spaces within the body, including blood vessels, the digestive tract and the respiratory system. It has the ability to move in tight spaces and curved passages as well as the ability to remain within the body for a prolonged period of time.

Contact Ellen Kelleher at [email protected]

View full MBOT profile View Profile

Microbot Medical Inc Timeline

Related Articles

scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use